Health and science are at the heart of everything we do

BioGaia is a world-leading Swedish healthcare company that has been at the forefront of microbiome research for more than 30 years, developing, marketing and selling clinically proven probiotic products.

We engage in operations across the entire value chain, partly internally and partly through an extensive network of independent researchers, production experts, and distribution partners. Our products are distributed by nutrition and pharmaceutical companies in more than 100 countries worldwide.

Our products contain strains of the lactic acid bacterium L. reuteri (Limosilactobacillus reuteri, formerly known as Lactobacillus reuteri). L. reuteri has co-evolved with humans and, as a result, has a strong adaptation and naturally colonizes and interacts with the human body. Our probiotic strains have been published in more than 200 articles in scientific journals, proving their effectiveness and safety.

Contact us Our products

 

Investors

BioGaia’s class B shares are listed on the Mid-cap segment of the Nasdaq OMX Nordic Stockholm exchange. Read more

Our business model

The BioGaia business model is built on three external networks - research, production, and distribution. As a result of this business model, we have been able to grow globally and operate as a lean, efficient, and agile company. Read more

Distribution network

BioGaia’s probiotic products are sold through approximately 80 distribution partners in 100 countries around the world.
Read more

BioGaia's history

The history of BioGaia dates back to the 1980s, a time when HIV/AIDS was first discovered. Two scientists, Sven Lindgren and Walt Dobrogosz, examined different probiotics with the aim of finding out what effect they had on the virus. Read more